Study Comparing Prevenar® to Pneumo 23 in Reducing Carriage in Children

Wyeth is now a wholly owned subsidiary of Pfizer101 enrolled

Overview

To compare the ability of Prevnar® to Pneumo® 23 in reducing and preventing nasopharyngeal carriage of vaccine-type pneumococci one year after respective immunization. To evaluate the rate of penicillin-resistant pneumococci in nasopharyngeal carriage.

This study will require 6 months to be completed (3 months for nasopharyngeal samples collection; 3 months dor analysis). Each child will participate for a 1 day period.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

101

Conditions

Vaccines, Pneumococcal Vaccines, Pneumococcal Conjugate Vaccine

Interventions

pneumococcus conjugate vaccine 7 valent to reduce carriageBIOLOGICAL

plain polisacaride vaccine 23 valent to reduce carriage

Eligibility

Sex: ALLMin age: 2 YearsMax age: 9 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy children between * 2 to 9 years old. * No history of antibiotic use prior 1 month of enrollment * No history of invasive pneumococcal disease

Outcomes

Primary Outcomes

To compare the ability of Prevnar® to Pneumo® 23 in reducing and preventing nasopharyngeal carriage of vaccine-type pneumococci one year after respective immunization.

Time frame: 12 months

Secondary Outcomes

To evaluate the rate of penicillin-resistant pneumococci in nasopharyngeal carriage.

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.